Order results by:
| Issue | Title | |
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY ..." | ||
| Vol 6, No 4 (2013) | Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа | Abstract similar documents |
| A. Yu. Kulikov, I. V. Novikov | ||
| "... and effectiveness in terms of QALY are compared for liraglutide, glimepiride and rosiglitazone, all in combination ..." | ||
| Vol 9, No 3 (2016) | METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... antibiotic in the therapy of acute obstructive bronchitis,. The highest value ICER ratio was obtained ..." | ||
| Vol 10, No 3 (2017) | Decision modelling for the evaluation of diabetes outcomes | Abstract similar documents |
| A. A. Mosikian, W. Zhao, T. L. Galankin, A. S. Kolbin | ||
| "... or to some aspects of the disease. Thus, the use of the novel anti-diabetic drugs (liraglutide, semaglutide ..." | ||
| Vol 11, No 4 (2018) | International experience in determining the cost-effectiveness thresholds | Abstract similar documents |
| T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky | ||
| "... -to-pay threshold (WTP), the threshold value of the incremental cost-effectiveness ratio (ICeR), in europe ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| Vol 13, No 4 (2020) | Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system | Abstract similar documents |
| T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky | ||
| Vol 10, No 3 (2017) | Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis | Abstract similar documents |
| E. V. Biryukova, V. I. Ignat’eva | ||
| "... (biphasic lispro 25). After 24 weeks, upon achieving or not achieving the target HbA1c values, a decision ..." | ||
| Vol 8, No 2 (2015) | SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS | Abstract similar documents |
| Georgii Rubenovich Khachatryan, Vladislav Sergeevich Dombrovskii | ||
| "... plus metformin achieved HbA1c <7% more frequently than those treated with saxagliptin plus metformin ..." | ||
| Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
| G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
| "... healthcare system point of view. Incremental cost-effectiveness ratio (ICER) for BV vs Ch ± RT and Ch ± RT ..." | ||
| Vol 5, No 3 (2012) | CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE | Abstract similar documents |
| E. E. Arinina, M. A. Rashyd | ||
| "... /аспарт в сравнении с НПХ/человеческими инсулинами для лечения больных сахарным диабетом 1-го типа и ..." | ||
| Vol 7, No 3 (2014) | PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA | Abstract similar documents |
| A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova | ||
| "... .1%. ICER for eloxatin was 8,801 and 18,162 compared to eksorum and platikad respectively. As a result ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment | Abstract similar documents |
| A. U. Kulikov, V. V. Babiy | ||
| Vol 12, No 3 (2019) | Availability and Pharmacoeconomics of Insulin Therapy in Countries with the Largest Number of Diabetics | Abstract PDF (Eng) similar documents |
| S. V. Ponomarenko | ||
| "... количеством пациентов с диабетом. Проанализирована медико-социальная и политико-экономическая значимость ..." | ||
| Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
| V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
| Vol 8, No 2 (2015) | ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA | Abstract similar documents |
| Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov | ||
| "... as it had clinical benefits with affordable additional expenses. The increment cost efficiency rate (ICER ..." | ||
| Vol 10, No 4 (2017) | PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... on the ICER analysis, the additional expenses associated with a wider use of preventive therapy in scenarios 1 ..." | ||
| Vol 14, No 1 (2021) | Perspectives of osteoarthritis prevention and therapy personification based on the analysis of comorbid background, genetic polymorphisms and microelement status | Abstract similar documents |
| I. Yu. Torshin, A. M. Lila, A. V. Naumov, I. S. Sardaryan, T. E. Bogacheva, T. R. Grishina, I. V. Gogoleva, O. A. Limanova, O. A. Gromova | ||
| "... , ожирение, сахарный диабет, эссенциальная (первичная) гипертензия, камни в почках и мочеточнике, острый ..." | ||
| Vol 8, No 1 (2015) | PHARMACOEPIDEMIOLOGICAL EVALUATION OF HEPATOTROPIC THERAPY IN REAL CLINICAL PRACTICE | Abstract similar documents |
| D. V. Blinov, U. V. Zimovina, T. I. Ushakova | ||
| "... заболевания печени наблюдались у 23,8% пациентов, ассоциированные с диабетом – у 13,7%. Хронические вирусные ..." | ||
| Vol 10, No 1 (2017) | THE PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN OUTPATIENTS IN THE FAR EAST FEDERAL DISTRICT | Abstract similar documents |
| V. A. Nevzorova, M. V. Mokshina, T. A. Brodskaya, D. A. Vasil’chenkov, D. V. Blinov, T. I. Ushakova | ||
| "... Стремительный рост заболеваемости такими патологиями, как ожирение и сахарный диабет, принимающий ..." | ||
| Vol 14, No 1 (2021) | Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19 | Abstract similar documents |
| O. V. Zhukova, A. L. Khokhlov | ||
| "... частности, терапия дексаметазоном должна проводиться с особой осторожностью у пациентов с сахарным диабетом ..." | ||
| 1 - 21 of 21 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
